Abstract
Influenza A virus (IAV) is one of the most common infectious pathogens in humans. Entry of this virus into cells is primarily determined by host cellular trypsin-type processing proteases, which proteolytically activate viral membrane fusion glycoprotein precursors. Human IAV and murine parainfluenza virus type 1 Sendai virus are exclusively pneumotropic, and the infectious organ tropism of these viruses is determined by the susceptibility of the viral envelope glycoprotein to cleavage by proteases in the airway. Proteases in the upper respiratory tract are suppressed by secretory leukoprotease inhibitor, and those in the lower respiratory tract are suppressed by pulmonary surfactant, which by adsorption inhibits the interaction between the proteases and viral membrane proteins. Although the protease activities are predominant over the activities of inhibitory compounds under normal airway conditions, intranasal administration of inhibitors was able to significantly suppress multi-cycles of viral replication in the airway. In addition, we identified chemical agents that could act as defensive factors by up-regulating the levels of the natural inhibitors and immunoglobulin A (IgA) in airway fluids. One of these compounds, ambroxol, is a mucolytic and anti-oxidant agent that stimulates the release of secretory leukoprotease inhibitor and pulmonary surfactant in the early phase, and IgA in the late phase of infection at an optimal dose, i.e. a dose sufficient to inhibit virus proliferation and increase the survival rate of animals after treatment with a lethal dose of IAV. Another agent, clarithromycin, is a macrolide antibiotic that increases IgA levels through augmentation of interleukin-12 levels and mucosal immunization in the airway. In addition to the sialidase inhibitors, which prevent the release of IAV from infected cells, inhibitors of the processing proteases and chemical agents that augment mucosal immunity and/or levels of the relevant defensive compounds may also ultimately prove to be useful as new anti-influenza agents.
References
Beppu, Y., Immamura, Y., Tashiro, M., Towatari, T., Ariga, H., and Kido, H. (1997). Human mucus protease inhibitor in airway fluids is a potential defensive compound against infection with influenza A and Sendai viruses. J. Biochem.121, 309–316.10.1093/oxfordjournals.jbchem.a021588Search in Google Scholar
Boyaka, P.N., Marinaro, M., Jackson, R.J., Menon, S., Kiyono, H., Jirillo, E., and McGhee, J.R. (1999). IL-12 is an effective adjuvant for induction of mucosal immunity. J. Immunol.162, 122–128.10.4049/jimmunol.162.1.122Search in Google Scholar
Chen, Y., Shiota, M., Ohuchi, M., Towatari, T., Tashiro, M., Murakami, M., Yano, M., Yang, B., and Kido, H. (2000). Mast cell tryptase from pig lungs triggers infection by pneumotropic Sendai and influenza viruses. Purification and characterization. Eur. J. Biochem.267, 3189–3197.10.1046/j.1432-1327.2000.01346.xSearch in Google Scholar
Gibbs, B.F., Schmutzler, W., Vollrath, I.B., Brosthardt, P., Braam, U., Wolff, H.H., and Zwadlo-Klarwasser, G. (1999). Ambroxol inhibits the release of histamine, leukotrienes and cytokines from human leukocytes and mast cells. Inflamm. Res.48, 86–93.10.1007/s000110050421Search in Google Scholar
Gillissen, A., Scharling, B., Jaworska, M., Bertling, A., Rasche, K., and Schulze-Werninghaus, G. (1997). Oxidant scavenger function of ambroxol in vitro: a comparison with N-acetyl-cysteine AC. Res. Exp. Med. (Berl.)196, 389–398.10.1007/s004330050049Search in Google Scholar
Grütter, M.G., Fendrich, G., Huber, R., and Bode, W. (1988). The 2.5 Å X-ray crystal structure of the acid-stable proteinase inhibitor from human mucous secretions analyzed in its complex with bovine α-chymotrypsin. EMBO J.7, 345–351.Search in Google Scholar
Homma, M., and Ohuchi, M. (1973). Trypsin action on the growth of Sendai virus in tissue culture cell. J. Virol.12, 1457–1465.10.1128/jvi.12.6.1457-1465.1973Search in Google Scholar
Kido, H., Yokogoshi, Y., Sakai, K., Rashiro, M., Kishino, Y., Fukutomi, A., and Katunuma, N. (1992). Isolation and characterization of a novel trypsin-like protease found in rat bronchiolar epithelial Clara cells. A possible activator of the viral fusion glycoprotein. J. Biol. Chem.267, 13573–13579.Search in Google Scholar
Kido, H., Sakai, K., Kishino, Y., and Tashiro, M. (1993). Pulmonary surfactant is a potential endogenous inhibitor of proteolytic activation of Sendai virus and influenza virus. FEBS Lett.322, 115–119.10.1016/0014-5793(93)81549-FSearch in Google Scholar
Kido, H., Beppu, Y., Imamura, Y., Chen, Y., Murakami, M., Oba, K., and Towatari, T. (1999). The human mucus protease inhibitor and its mutants are novel defensive compounds against infection with influenza A and Sendai viruses. Biopolymers51, 79–86.10.1002/(SICI)1097-0282(1999)51:1<79::AID-BIP9>3.0.CO;2-WSearch in Google Scholar
Klenk, H.-D., and Rott, R. (1988). The molecular biology of influenza virus pathogenicity. Adv. Virus Res.34, 247–281.10.1016/S0065-3527(08)60520-5Search in Google Scholar
Klenk, H.D., and Garten, W. (1994). Host cell processing proteases controlling virus pathogenicity. Trends Microbiol.2, 39–42.10.1016/0966-842X(94)90123-6Search in Google Scholar
Lee, C.H., Igarashi, A., Hohman, R.J., Kaulbach, H., White, M.V., and Kaliner, M.A. (1993). Distribution of secretory leukoprotease inhibitor in the human nasal airway. Am. Rev. Respir. Dis.147, 710–716.10.1164/ajrccm/147.3.710Search in Google Scholar
Liew, F.Y., Russell, S.M., Appleyard, G., Brand, C.M., and Beale, J. (1984). Cross-protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA rather than serum antibody or cytotoxic T cell reactivity. Eur. J. Immunol.14, 350–356.10.1002/eji.1830140414Search in Google Scholar PubMed
Lucey, E.C., Stone, P.J., Ciccolella, D.E., Brener, R., Christensen, T.G., Thompson, R.C., and Snider, G.L. (1990). Recombinant human secretory leukocyte-protease inhibitor: in vitro properties, and amelioration of human neutrophil elastase-induced emphysema and secretory cell metaplasia in the hamster. J. Lab. Clin. Med.15, 224–232.Search in Google Scholar
McElvaney, N.G., Doujaiji, B., Moan, M.J., Burnham, M.R., Wu, M.C., and Crystal, R.G. (1993). Pharmacokinetics of recombinant secretory leukoprotease inhibitor aerosolized to normals and individuals with cystic fibrosis. Am. Rev. Respir. Dis.148, 1056–1060.10.1164/ajrccm/148.4_Pt_1.1056Search in Google Scholar PubMed
Mooren, H.W.D., Kramps, J.A., Franken, C., Meijer, C.J.L.M., and Dickman, J.A. (1983). Localization of a low-molecular-weight bronchial protease inhibitor in the peripheral human lung. Thorax38, 180–183.10.1136/thx.38.3.180Search in Google Scholar PubMed PubMed Central
Murakami, M., Towatari, T., Ohuchi, M., Shiota, M., Akao, M., Okumura, Y., Parry, M.A.A., and Kido, H. (2001). Mini-plasmin found in the epithelial cells of bronchioles triggers infection by broad-spectrum influenza A viruses and Sendai virus. Eur. J. Biochem.268, 2847–2855.10.1046/j.1432-1327.2001.02166.xSearch in Google Scholar PubMed
Ohlsson, M., Rosengren, M., Tegner, H., and Ohlsson, K. (1983). Quantification of granulocyte elastase inhibitors in human mixed saliva and pure parotid secretion. Hoppe-Seyler’s Z. Physiol. Chem.364, 1323–1328.10.1515/bchm2.1983.364.2.1323Search in Google Scholar PubMed
Pfeifer, S., Zissel, G., Kienast, K., and Muller-Quernheim, J. (1997). Reduction of cytokine release from blood and bronchoalveolar mononuclear cells by ambroxol. Eur. J. Med. Res.2, 129–132.Search in Google Scholar
Puchelle, E.J., Hinnraski, J., Tournier, J.M., and Adnet, J.J. (1985). Ultrastructural localization of bronchial inhibitor in human airways using protein A-gold technique. Biol. Cell55, 151–154.10.1111/j.1768-322X.1985.tb00418.xSearch in Google Scholar PubMed
Sato, M., Yoshida, S., Iida, K., Tomozawa, T., Kido, H., and Yamashita, M. (2003). A novel influenza A virus activating enzyme from porcine lung: purification and characterization. Biol. Chem.384, 219–227.10.1515/BC.2003.024Search in Google Scholar PubMed
Stolk, J., Rossie, W., and Dijkman, J.H. (1994). Apocynin improves the efficacy of secretory leukocyte protease inhibitor in experimental emphysema. Am. J. Respir. Crit. Care Med.150, 1628–1631.10.1164/ajrccm.150.6.7952625Search in Google Scholar PubMed
Tamura, S., Miyata, K., Matsuo, K., Asanuma, H., Takahashi, H., Nakajima, K., Suzuki, Y., Aizawa, C, and Kurata, T. (1996). Acceleration of influenza virus clearance by Th1 cells in the nasal site of mice immunized intranasally with adjuvant-combined recombinant nucleoprotein. J. Immunol.156, 3892–3900.10.4049/jimmunol.156.10.3892Search in Google Scholar
Tashiro, M., Beppu, Y., Sakai, K., and Kido, H. (1996). Inhibitory effect of pulmonary surfactant on Sendai virus infection in rat lungs. Arch. Virol.141, 1571–1577.10.1007/BF01718255Search in Google Scholar PubMed
Towatari, T., Ide, M., Ohba, K., Chiba, Y., Murakami, M., Shiota, M., Kawachi, M., Yamada, H., and Kido, H. (2002). Identification of ectopic anionic trypsin I in rat lungs potentiating pneumotropic virus infectivity and increased enzyme level after virus infection. Eur. J. Biochem.269, 1–9.10.1046/j.1432-1033.2002.02937.xSearch in Google Scholar PubMed
Tsurita, M., Kurokawa, M., Imakita, M., Fukuda, Y., Watanabe, Y., and Shiraki, K. (2001). Early augmentation of interleukin (IL)-12 level in the airway of mice administered orally with clarithromycin or intranasally with IL-12 results in alleviation of influenza infection. J. Pharmacol. Exp. Ther.298, 362–368.Search in Google Scholar
Van-Seuningen, I., and Davril, M. (1991). Separation of the two domains of human mucus proteinase inhibitor: inhibitory activity is only located in the carboxy-terminal domain. Biochem. Biophys. Res. Commun.179, 1587–1592.10.1016/0006-291X(91)91755-2Search in Google Scholar
Vogelmeier, C., Hubbard, R.C., Fells, G.A., Schnebli, H.-P., Thompson, R.C., Fritz, H., and Crystal, R.G. (1991). Anti-neutrophil elastase defense of the normal human respiratory epithelial surface provided by the secretory leukoprotease inhibitor. J. Clin. Invest.87, 482–488.10.1172/JCI115021Search in Google Scholar PubMed PubMed Central
Willems, L.N.A., Kramps, J.A., Stijnen, T., Sterk, P.J., Weening, J.J., and Dijkman, J.M. (1989). Relationship with morphologic disease of small airways and parenchyma. Am. Rev. Respir. Dis.139, 1244–1250.10.1164/ajrccm/139.5.1244Search in Google Scholar PubMed
Wright, P. F., Murphy, B.R., Kervina, M., Lawrence, E.M., Phelan, M.A., and Karzon, D.T. (1983). Secretory immunological response after intranasal inactivated influenza A virus vaccinations: evidence for immunoglobulin A memory. Infect. Immun.40, 1092–1095.10.1128/iai.40.3.1092-1095.1983Search in Google Scholar PubMed PubMed Central
Yang, B., Yao, D.F., Ohuchi, M., Ide, M., Yano, M., Okumura, Y., and Kido, H. (2002). Ambroxol suppresses influenza-virus proliferation in the mouse airway by increasing antiviral factor levels. Eur. Res. J.19, 952–958.10.1183/09031936.02.00253302Search in Google Scholar PubMed
Yao, D., Chen, Y., Kuwajima, M., Shiota, M., and Kido, H. (2004). Accumulation of mini-plasmin in the cerebral capillaries causes vascular invasion of the murine brain by a pneumotropic influenza A virus: implications for influenza-associated encephalopathy. Biol. Chem.385, 487–492.10.1515/BC.2004.057Search in Google Scholar PubMed
© Walter de Gruyter
